Ultomiris® (ravulizumab-cwvz) – New orphan indication
October 18, 2019 - Alexion Pharmaceuticals announced the FDA approval of Ultomiris (ravulizumab-cwvz), for the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).
Top